Recombinant Respiratory Syncytial Virus pre-fusion F protein (RSVPreF3)
Consumer Medicine Information
This leaflet provides important information about using AREXVY. You should also speak to your doctor or nurse if you would like further information or if you have any concerns or questions about using AREXVY.
Where to find information in this leaflet:
- Why am I being given AREXVY?
- What should I know before I am given AREXVY?
- What if I am taking other medicines?
- How is AREXVY given?
- What should I know when being given AREXVY?
- Are there any side effects?
- Product details
1. Why am I being given AREXVY?
AREXVY is a vaccine that contains the active ingredient Recombinant Respiratory Syncytial Virus pre-fusion F protein (RSVPreF3). It is mixed with an adjuvant suspension to form the vaccine that you will receive.
The adjuvant is used to improve the body’s response to the vaccine.
AREXVY helps to protect adults over the age of 60 against RSV infection.
Respiratory Syncytial Virus (RSV) is a highly contagious respiratory virus that causes infections of the lungs and breathing passages. It usually causes mild, cold-like symptoms in adults and infection can occur at any age.
RSV can also cause more serious respiratory illnesses in infants and older adults. It can lead to serious illness such as pneumonia and RSV infection may also worsen some existing conditions such as long-term respiratory conditions or heart disease.
The vaccine works by helping your body make antibodies and special white blood cells to reduce your chances of experiencing a serious illness due to RSV infection.
AREXVY does not contain the RSV virus and it cannot cause lung infection.
As with all vaccines, AREXVY may not fully protect all people who are vaccinated.
2. What should I know before I am given AREXVY?
Warnings
Do not use AREXVY if:
- you are allergic to AREXVY, or any of the ingredients listed at the end of this leaflet.
Always check the ingredients to make sure you can use this vaccine.
Published by MIMS March 2024